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ABSTRACT: Four HIV-1 protease (PR) inhibitors, clinical
inhibitors lopinavir and tipranavir, and two investigational
compounds 4 and 5, were studied for their eﬀect on the
structure and activity of PR with drug-resistant mutation
L76V (PRL76V). Compound 5 exhibited the best Ki value of
1.9 nM for PRL76V, whereas the other three inhibitors had Ki
values of 4.5−7.6 nM, 2−3 orders of magnitude worse than
for wild-type enzymes. Crystal structures showed only minor
diﬀerences in interactions of inhibitors with PRL76V compared to wild-type complexes. The shorter side chain of Val76 in the
mutant lost hydrophobic interactions with Lys45 and Ile47 in the ﬂap, and with Asp30 and Thr74 in the protein core, consistent
with decreased stability. Inhibitors forming additional polar interactions with the ﬂaps or dimer interface of PRL76V were unable
to compensate for the decrease in internal hydrophobic contacts. These structures provide insights for inhibitor design.
■ INTRODUCTION
The protease (PR) encoded by the human immunodeﬁciency
virus (HIV) is an important drug target for treatment of the
pandemic disease HIV/AIDS. A decrease in AIDS-associated
deaths was observed in the mid-90s because of the inclusion of
both PR inhibitors (PIs) with reverse transcriptase inhibitors in
therapy.1 Despite this notable success, the rapid evolution of
drug-resistant viral strains poses a critical challenge, and drug-
resistant mutations have been observed for all classes of
antiviral drugs.2 HIV PR performs an essential role in viral
replication by processing the viral precursor polyproteins into
mature viral proteins. Inhibitors bind in the active-site cavity of
dimeric HIV PR and block its catalytic activity. More than 100
mutations in the PR gene have been associated with drug
resistance.3
Second-generation inhibitors, such as darunavir (1),
lopinavir (2), and tipranavir (3) (Figure 1), were designed
to target resistant variants of HIV-1 PR. The peptidomimetic
inhibitor 2 resembles the natural PR substrate with P2−P3′
groups.4,5 Inhibitor 3 is a highly potent, nonpeptidic PI with a
unique oxygen that displaces conserved active-site water and
forms direct hydrogen bonds with the main chain amides of
Ile50/Ile50′.6,7 The most-recently approved inhibitor, 1,
exhibits low toxicity and is equipped with P2/P2′ groups
that form strong hydrogen bonds with conserved, main chain
atoms, resulting in high binding aﬃnity for PR.8−10 Because of
these favorable factors, resistance mutations rarely develop
during treatment with 1.11
The evolution of resistance toward second-generation
inhibitors has fueled the design of novel investigational
inhibitors. Compounds GRL-0519 (4) and GRL-5010 (5),
derived from the scaﬀold of 1, are highly potent against several
drug-resistant variants (Figure 1). Inhibitor 4 has an enlarged
tristetrahydrofuran P2 group, which ﬁts better in the S2 pocket
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Figure 1. Structures of HIV-1 PIs 1−6.
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of PR and reinforces a water-mediated network at the dimer
interface.12−14 Inhibitor 5 diﬀers from 1 by addition of a gem-
diﬂuoro moiety on the P2 bis-THF group, which improves
lipophilicity and forms halogen bond interactions with the
carbonyl oxygen of ﬂap residue Gly48.15−17
Mutation L76V is associated with clinical resistance to 1,
fosamprenavir, 2, and indinavir;2,18 however, it is also linked
with increased susceptibility to ﬁrst-generation inhibitor
saquinavir (6), atazanavir, and 3.19,20 This mutation occurs
with a frequency of around 3% in PI-experienced patients20,21
and can be transmitted to treatment-naive patients.22,23
Inclusion of L76V in mutants bearing three other resistance
mutations is associated with two- and eightfold increase in
resistance to 1 and 2, respectively, and an eightfold increase in
susceptibility to 6.20
Previous studies of PR with the single mutation of L76V
(PRL76V) showed about 100-fold worse inhibition by 1
compared to wild-type PR (PRWT) as assessed by isothermal
titration calorimetry,24 although another group using an
enzyme inhibition assay reported only 1.5-fold loss in
potency.25 Investigational inhibitor GRL-02031 showed a
twofold increase in inhibition constant (Ki) for PRL76V in
comparison to PRWT.
26 Crystal structures of PRL76V in
complexes with 1 and 6 showed loss of interactions with 1
and gain of a water-mediated interaction with 6 relative to
PRWT,
24,25 consistent with the eﬀects on resistance.20 These
eﬀects on inhibitors must be indirect as the side chain of Leu76
lies in the interior of the PR dimer and has no van der Waals
contacts with these antiviral inhibitors. In the mutant structure,
the smaller Val76 side chain has lost hydrophobic interactions
with neighboring side chains of Asp30, Lys45, Ile47, and
Thr74 compared with those of the wild-type Leu76, consistent
with decreased stability and slower autoprocessing observed
for the mutant and its precursor.24,26
Here, we have assessed the eﬀect of four antiviral inhibitors,
clinical inhibitors 2 and 3 and investigational inhibitors 4 and
5, on the structure and activity of the PRL76V mutant. Clinical
inhibitor 2 was selected because L76V is associated with an
eightfold increase in resistance to this PI as inferred from
genotype−phenotype data.20 Fluorine-containing inhibitors, 3
and 5, form direct interactions with ﬂap residues of the PR,7,16
potentially stabilizing the PR dimer. The larger P2 group and
reinforced dimer interface interactions of compound 4 also
might overcome the decreased dimer stability observed for
PRL76V.
12,24 The results show that these chemically diverse
inhibitors lose potency against PRL76V, and suggest that local
rearrangements in the hydrophobic core because of mutation
L76V act to decrease the eﬀectiveness of the inhibitors.
■ RESULTS
Tested Inhibitors Have Higher Ki Values for PRL76V
Relative to PRWT. Inhibition constants (Ki) of the compounds
for PRL76V were determined using a ﬂuorescent substrate
analog of the HIV-1 p2/NC cleavage site. Table 1 lists Ki
values for the mutant in comparison with values reported
previously for wild-type enzymes.7,12,16 As reported previously,
inhibitor 1 has the best inhibition of this mutant,24 whereas
inhibitor 6 retains a similar inhibition of mutant relative to
wild-type enzymes.27,28 Compound 5 is the most potent of the
new inhibitors for PRL76V with a Ki of 1.9 ± 0.7 nM, whereas 3
and 4 are the worst of the tested inhibitors with Ki of 7.6 ± 0.3
and 7.2 ± 1.4 nM, respectively. Therefore, the tested inhibitors
are within a 10-fold diﬀerence in potency from each other for
PRL76V inhibition. With the exception of 6, all Ki values
measured for inhibition of PRL76V were signiﬁcantly higher
than the picomolar Ki values reported for wild-type PR with
changes of 1200-fold for 4, 400-fold for 3, 300-fold for 5, 150-
fold for 2, and 80-fold for 1.7,12,16 These higher Ki values imply
that L76V confers resistance toward the four tested inhibitors.
Structures of the PRL76V Dimer with Inhibitor
Resemble Each Other as Well as Their PRWT Counter-
parts. Crystal structures of PRWT complexed with PIs 2 and 3,
and of PRL76V complexed with each of the four inhibitors, were
determined at high resolution to identify any structural
changes because of the single mutation (Table 2). The
dimer of PRL76V with 2 and the location of residue 76 are
illustrated in Figure 2A. All PRL76V structures were solved in
the P21212 space group with one dimer in the asymmetric unit,
as were PRWT complexes with inhibitors 2 and 3 in the present
study and in previous studies [PRWT complexes with 4 and 5 at
1.27 Å (PDB ID 3OK9) and 1.30 Å (PDB ID 4U8W),
respectively].12,16
The unit cell dimensions were almost identical for all
structures, although 2 complexes had ∼1 Å longer a axis and
∼1 Å shorter b axis compared to the other structures. The six
structures were reﬁned to R-factors of 15.1−19.8% with
diﬀraction data at a 1.20−1.75 Å resolution. Atoms were
unambiguously modeled, as shown by the electron density map
in Figure 2B for the single conformation of 2 in complex with
PRL76V. Coordinate errors estimated from Luzzati plots ranged
from 0.14 to 0.18 Å for the highest to lowest resolution
structures.
The new PRWT complexes with 2 and 3 were reﬁned at near-
atomic resolutions of 1.26 and 1.20 Å, respectively, which is a
signiﬁcant improvement compared to previously reported
structures determined at 1.54 and 1.80 Å resolutions,
respectively.7 The previous PRWT structures in complex with
2 (PDB ID 2O4S) or 3 (PDB ID 2O4P) were solved in the
same space group, and the Cα atoms superimposed with the
new higher resolution structures with root-mean-square
deviation (rmsd) values of 0.19 Å for complexes with 3 and
0.20 Å for complexes with 2. Therefore, the overall folds are
very similar.
The four new PRL76V inhibitor structures were superimposed
with their corresponding PRWT inhibitor complexes. The
overall backbone structures were essentially identical, with low
rmsd values ranging from 0.12 to 0.17 Å for all Cα atoms.
Therefore, mutation L76V does not produce major alterations
in the overall structure of the PR dimer. Furthermore, all
PRL76V structures were also very similar to each other,
regardless of the inhibitor, with pairwise rmsd values ranging
from 0.25 to 0.42 Å.
Polar Interactions are Conserved between Active-
Site Residues and Inhibitors. Hydrogen bonds between PR
Table 1. Inhibition Constants for PRL76V and Wild Type PR
compound PRL76V (nM) PRWT (nM) fold-change
1 0.79a 0.010b 80
6 1.5 ± 0.2 0.4−2.0c 4−0.8
5 1.9 ± 0.7 0.006d 300
2 4.5 ± 0.5 0.031b 150
4 7.2 ± 1.4 0.006e 1200
3 7.6 ± 0.3 0.019b 400
aValue from ref 24. bValue from ref 7. cValues from refs.27,28 dValue
from ref 16. eValue from ref 12.
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and inhibitor, both direct and water-mediated, were compared
for wild-type and mutant PR complexes. Halogen bonds were
also observed for two inhibitors, 3 and 5, containing ﬂuorine
atoms. The interactions are described for the major
conformations of inhibitors in the complexes. Similar
interactions were observed for the minor conformations except
where noted.
Hydrogen bond interactions in X-ray crystal structures of
proteins must be interpreted with caution as hydrogen atoms
are poorly scattered by X-rays. Neutron crystallography,
however, provides direct evidence for the position of protons.
The neutron crystal structure of HIV PR with amprenavir
showed nonideal hydrogen bond geometry for inhibitor
interactions with the carbonyl oxygen of Gly27, the amide of
Asp29, and a water-mediated interaction with the amide of
Ile50′.29 Similar eﬀects were observed for the neutron structure
of amprenavir complexed with PR mutant V32I/I47V/V82I.30
No neutron crystal structures have been reported for the
inhibitor complexes in this study; hence, hydrogen bonds for
L76V complexes are described by the same criteria as for
previously published wild-type complexes (Figure 3).
All clinical inhibitors contain a central hydroxyl group that
interacts with the catalytic aspartates, residues 25 and 25′, of
PR. The protonation state and hydrogen bond interactions of
the catalytic residues, Asp25 and 25′, have been examined in
several neutron structures. The side chain carboxylate oxygens
of Asp25 and 25′ are almost coplanar with about 2.7 Å
between the closest “inner” oxygens of the two side chains.
Our neutron structure of wild-type HIV PR with amprenavir
showed two protons located on the inner carboxylate oxygen
of Asp25 and the outer carboxylate oxygen of Asp25′, which
formed hydrogen bonds with the inhibitor hydroxyl.29
Subsequent neutron studies of 1 and amprenavir complexes
with a mutant PR demonstrated that the location of the two
protons varies, depending on the pH, inhibitor, and mutated
residues.30,31 In our X-ray structures of inhibitor-bound
PRL76V, we cannot distinguish which hydrogen bond
interactions occur with the inhibitor hydroxyl group. In the
absence of neutron structures corresponding to the PR
complexes with the inhibitors described here, we have
indicated distances for four possible interactions between the
hydroxyl oxygen of the inhibitor and carboxylate oxygens of
Table 2. Crystallographic Data Collection and Reﬁnement Statisticsa
PRWT−2 PRL76V−2 PRWT−3 PRL76V−3 PRL76V−4 PRL76V−5
space group P21212 P21212 P21212 P21212 P21212 P21212
Cell Dimensions
a (Å) 59.73 60.01 58.30 58.60 58.67 58.26
b (Å) 85.20 85.38 86.26 86.40 86.34 86.05
c (Å) 46.27 46.43 46.01 46.16 46.00 46.25
resolution range (Å) 50.00−1.26 50.00−1.36 50.00−1.20 50.00−1.47 50.00−1.75 50.00−1.31
unique reﬂections 64 844 47 855 71 617 38 910 24 343 55 212
redundancy 3.9 (3.2) 6.1 (2.4) 5.2 (3.2) 4.0 (3.7) 4.8 (4.9) 4.4 (1.8)
completeness 98.9 (92.0) 91.9 (53.9) 97.6 (85.4) 99.6 (98.9) 100.0 (100.0) 96.0 (77.6)
I/sigma 13.7 (2.1) 30.8 (3.3) 15.9 (2.0) 11.5 (3.4) 21.7 (4.2) 13.3 (2.1)
Rsym (%) 6.7 (49.5) 4.4 (31.0) 9.7 (44.4) 8.8 (49.9) 6.6 (40.5) 8.7 (45.4)
reﬁnement resolution range (Å) 50.00−1.26 50.00−1.36 50.00−1.20 50.00−1.47 50.00−1.75 50.00−1.31
R (%) 17.3 15.1 15.4 16.3 19.8 15.8
Rfree (%) 20.8 19.6 18.7 21.4 24.3 20.5
number of solvent molecules 195 280 217 153 161 197
Average B-Factor (Å2)
main chain 15.6 14.2 12.5 14.5 16.1 21.2
side chain 21.9 19.7 17.2 20.7 22.3 26.7
inhibitor 12.9 15.8 13.4 16.9 11.0 18.1
solvent 26.0 26.5 25.6 32.5 26.6 32.3
rms Deviation from Ideality
bond length (Å) 0.012 0.011 0.014 0.010 0.006 0.012
angles (Å) 0.030 0.028 0.034 0.029 0.023 0.032
aValues in parentheses are given for the highest resolution shell.
Figure 2. Structure of the PRL76V dimer with inhibitor 2. (A)
Structure of the PRL76V dimer in complex with inhibitor 2. The two
subunits are shown in light and dark gray ribbons. Inhibitor 2 is
shown with green bonds. The side chain of Val76 is in red sticks; side
chains of residues that interact with the Leu76 side chain are shown as
purple sticks. Side chains were omitted on second subunit for clarity.
(B) Electron density map for single conformation of inhibitor 2
(green sticks) bound in the PRL76V dimer. 2Fo − Fc electron density
map contoured at the 1.0σ level is represented by the purple mesh.
The view is rotated about 90° from (A). Flap residues 46−57 in
subunit (A) and 48−54 in subunit (B) have been removed for clarity.
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Asp25 and 25′ in Figure 3. These interactions are excluded
from the description of inhibitor−PR hydrogen bonds in the
following sections.
Although inhibitor 2 occurs in two alternative conformations
with relative occupancy of 75:25 in the wild-type complex, only
a single conformation was observed for 2 bound to PRL76V.
Excluding interactions with the catalytic Asp25 and 25′,
compound 2 shows only three direct hydrogen bonds with
PRL76V and three water-mediated interactions with main chain
atoms (Figure 3A). The interactions are in agreement with
those reported previously.7 Compound 2 has a pseudosym-
metric structure for the central P1−P1′ region. The water-
mediated interactions with the amides of Ile50 and 50′ in the
ﬂaps are conserved in the majority of PR−inhibitor complexes.
The pyrimidine acetamide group of 2 forms hydrogen bonds
with the main chain amide and carboxylate side chain of Asp29
and a water-mediated interaction with the carbonyl oxygen of
Gly27. These hydrogen bonds contribute to a network of
interactions at the dimer interface connecting Gly27 and
Asp29 in one subunit with Arg8′ in the second subunit. The
hydrophobic dimethylphenoxy group on the opposite end of 2
has van der Waals interactions with the side chains of Ala28′,
Asp29′, Asp30′, Val32′, Ile47′ and Ile84′. Inhibitor 2 shows
highly conserved hydrogen bond interactions in the complexes
with PRWT and PRL76V with diﬀerences in hydrogen bond
length of no more than 0.2 Å. Therefore, the decreased
potency of 2 toward PRL76V cannot be explained by changes in
PR interactions with the inhibitor.
The distinctive features of the interactions of compound 3
with PR are the presence of direct hydrogen bonds of the
inhibitor with the amides of ﬂap residues Ile50 and Ile50′, as
well as ﬂuoride halogen bonds with the guanidinium side chain
group of Arg8′. None of the other clinical inhibitors can form
these interactions. Furthermore, 3 adopts a bent conformation
at the sulfonamide group, and does not bind in the same
pockets as more peptidic inhibitors. As shown in Figure 3B,
inhibitor 3 has ﬁve direct hydrogen bonds with the PR, two
halogen interactions with the guanidinium side chain of Arg8′,
and a water-mediated interaction with the amide of Gly48. The
carboxylate groups of the catalytic Asp25 and Asp25′ are
rotated in the 3 complex relative to their orientation in the
complexes with other inhibitors and show altered distances to
the hydroxyl of 3. Inhibitor 3 retains wild-type hydrogen-
bonding interactions with the PRL76V mutant, with 0.1 Å
diﬀerence in distance observed for most interactions. The
largest increases of 0.2 and 0.3 Å in the mutant are seen for the
hydrogen bond to the carbonyl oxygen of Gly48 and the water-
mediated interaction with the amide of Gly48, respectively.
Thus, 3 forms direct hydrogen bonds with the main chain
atoms of ﬂap residues, Gly48, Ile50, and Ile50′ in both wild-
type and mutant PRs. Inhibitor 3 shows two alternative
conformations in both complexes with 70:30 relative
occupancy; the minor conformation with 30% occupancy
loses a hydrogen bond to the amide of Asp29 in the mutant
structure. The conservation of 3 interactions with PRL76V and
wild-type enzyme implies that the poor Ki value for the mutant
does not arise from altered binding interactions.
In both the PRWT and mutant complexes, compound 4 binds
in two alternative conformations with 50:50 relative
occupancy. Inhibitor 4 forms ﬁve direct hydrogen bonds
with PR and three water-mediated interactions in both mutant
and wild-type complexes (Figure 3C). In comparison to the
wild-type complex, both conformations of 4 in the mutant
show a slight shift of the water interacting with the amides of
Ile50 and Ile50′, yet this change maintains the interactions
with the ﬂaps. A second water, which is highly conserved in
many PR structures and was mentioned earlier in the
description for complexes with 2, is integrated into a dimer-
stabilizing network of interactions that coordinates the tris-
THF rings of 4, the carbonyl oxygen of Gly27, and the side
Figure 3. Polar interactions of PRL76V with inhibitors. (A) Inhibitor 2 (green); (B) inhibitor 3 (yellow); (C) inhibitor 4 (cyan); and (D) inhibitor
5 (salmon). PR residues are shown in gray sticks with alpha-carbons as spheres; nitrogen (blue), oxygen (red), ﬂuorine (pale cyan), water (red
spheres). Side chains without polar interactions with inhibitors are omitted. Hydrogen bond interactions conserved in wild-type and mutant PR are
shown as black dashed lines. Interactions that do not form in the mutant are shown as red dashed lines. Halogen bonds are in green dotted lines.
Interatomic distances are given in Å for PRL76V (black) and PRWT (red in parenthesis) if values diﬀer by 0.3 Å or more. In (D), Asp30 and Asp30′
are shown in two alternate conformations, and the interactions of Asp30′ with P2′ group of inhibitors diﬀer for the alternate conformations.
Distances for the (B) conformation of Asp30′ are shown after a forward slash.
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chains of Asp29 and Arg8′. Compared to the wild-type
complex, most hydrogen bond interactions between inhibitors
and PRL76V have insigniﬁcant changes of less than 0.1 Å.
Greater variation is observed for the interactions with the ﬂap
water with diﬀerences of up to 0.4 Å in length. One alternate
conformation in both wild-type and mutant structures shows
longer 3.4−3.5 Å hydrogen bonds between the tris-THF group
of 4 and the amides of Asp29 and Asp30. Once again, the lack
of signiﬁcant diﬀerences in PR active-site interactions with 4
indicates that the resistance mechanism induced by L76V relies
on an alternate strategy.
Compound 5 crystallized in two alternate conformations in
PRWT as well as in PRL76V with 55:45 relative occupancy.
Overall, PRWT shows seven direct hydrogen bond interactions,
two halogen bond interactions, and three water-mediated
interactions with the major conformation of 5 (Figure 3D).
The majority of the direct hydrogen bond interactions of
PRL76V with inhibitors are identical in length or within a 0.1 Å
range from those observed in the wild-type complex. Asp30
and Asp30′ occur in two alternate conformations, resulting in
diﬀerences in the interactions of the P2 aniline group of
inhibitors with Asp30′ in the PRL76V structure. In the wild-type
complex, the amino group of P2 forms hydrogen bond
interactions with the side chain carboxylate of Asp30′ and with
the main chain amide and carbonyl oxygen. In the PRL76V
structure, the P2 aniline has shifted slightly relative to its
position in the wild-type complex. In the major conformation
of Asp30′ in the mutant, the carboxylate side chain is
positioned to form a shorter hydrogen bond interaction with
the aniline amino group relative to the wild-type complex,
whereas the hydrogen bond of the main chain amide of Asp30′
with the inhibitor NH2 is elongated to 3.5 Å, and the
interaction of the main chain carbonyl oxygen with inhibitor is
lost (interatomic distance of 4.4 Å). Similar shifts in P2 aniline
and altered interactions with Asp30′ were reported for the
PRL76V complex with 1.
24 This major conformation of Asp30′
is stabilized by an ionic interaction with the side chain of
Lys45′. The minor conformation of the Asp30′ side chain has
rotated away from the inhibitor; however, the main chain
amide and carbonyl oxygen form hydrogen bonds of 3.0 and
3.3 Å, respectively, with NH2 of inhibitors. Although 5 is the
most eﬀective of the four tested inhibitors for PRL76V, it did not
retain the picomolar inhibition reported for wild-type enzymes.
Overall, the interactions of the major conformation of 5 with
Asp30′ are altered in the mutant; however, the rest of the
hydrogen-bonding network is maintained. Therefore, the loss
in potency against the mutant is not completely explained by
interactions between inhibitors and PR.
Polar and hydrophobic interactions of inhibitors 1−6 with
mutant PRL76V and wild-type enzyme are summarized in Table
3. Hydrogen bond interactions include direct inhibitor−
protein interactions and water-mediated interactions and
showed little change for alternate conformations of inhibitors.
The count of van der Waals contacts is complicated by the
existence of alternate conformations of inhibitors, and
frequently for adjacent amino acid side chains or main chains.
The exact contacts may be impossible to determine when
alternate conformations show 50:50 relative occupancy and, in
fact, multiple conformations will contribute to the ensemble
present in solution. The binding aﬃnities of clinical inhibitors
for wild-type PR have been divided into enthalpic and entropic
components using isothermal scanning calorimetry.7,28 The
binding of inhibitors 2, 3, and 6 is dominated by the large
entropic component, and only inhibitor 1 showed enthalpically
driven binding to wild-type PR. This thermodynamic analysis
implies that in most cases inhibition cannot easily be assessed
by summing inhibitor−PR interactions. In fact, thermody-
namic dissection of inhibitor aﬃnity for mutant PRs showed
unfavorable changes in both entropic and enthalpic compo-
nents.7 Inhibitor 1 loses hydrogen bond interactions with
mutant PRL76V, countered by a small increase in hydrophobic
contacts, and worse inhibition of the mutant. Inhibitor 6
showed gains in hydrogen bond and hydrophobic interactions
with this mutant in agreement with insigniﬁcant diﬀerences in
inhibition compared to wild-type enzymes. Apart from
inhibitor 2, the other inhibitors showed fewer hydrophobic
contacts with mutants as well as worse inhibition values.
Hydrophobic Interactions of Leu76 are Decreased in
the PRL76V Mutant. Residue 76 occupies a region critical for
internal hydrophobic contacts between the ﬂap and the core of
the protein. Residue 76 lies in the central strand of a three-
stranded β-sheet forming one ﬂank of the substrate binding
cavity near the base of the ﬂap (Figure 2). The mobility of the
ﬂaps is essential for substrate binding and catalysis as the ﬂaps
act as lids over the active-site cavity and must open to allow
substrate entry and release of products.32 Consequently,
altered ﬂap dynamics has been reported for drug-resistant
mutants.25,27,33,34
In all the structures of PRWT and PRL76V with various
inhibitors, the main chain of residue 76 forms conserved
hydrogen bond interactions with adjacent strands of the β-
sheet comprising residues 31−33 and 57−59. In addition, the
side chain of residue 76 forms hydrophobic interactions with
the side chains of Val32, Val56, and Gln58 (Figure 4).
Furthermore, the wild-type residue, Leu76, forms van der
Waals interactions with Asp30, Thr74, and with the side chains
of Lys45 and Ile47 in the ﬁrst β-strand of the two-stranded ﬂap
(Figure 4A). These interactions of Leu76 with residues 30−33
and both strands of the ﬂap are conserved in the open
conformation of the PR dimer (PDB ID 2PC0).35 However, in
the PRL76V mutant, the shorter side chain of Val76 loses
hydrophobic contacts with the ﬁrst β-strand of the ﬂaps, and
additionally loses interactions with Asp30 and Thr74 (Figure
4B). These changes agree with those reported previously for
PRL76V complexes with 1 and 6.
24
The ﬂap−core interface is composed of residues Lys45,
Ile47, Ile54, Val56, and Gln58 in the ﬂap, residues Asp30 and
Val32 in the inhibitor binding site, and Thr74 and Leu76 in
the protein core. The side chains of these residues form
hydrophobic interactions and shield the interface from the
solvent. Leu76 is a central component of the ﬂap−core
Table 3. Summary of Inhibitor−PR Interactionsa
inhibitor MW
PRWT
H-bondb
PRL76V
H-bondb
PRWT
vdWc
PRL76V
vdWc
1 548 7 + 2 5 + 2 136(140) 152(157)
6 671 4 + 3 5 + 4 141(138) 173(173)
5 584 7 + 3 6 + 3 171(146) 150(137)
2 629 3 + 3 3 + 3 184(151) 191
4 605 5 + 3 5 + 3 170(173) 155(163)
3 603 5 + 1 5 + 1 161(161) 157(147)
aCompounds are listed in order of best to worst inhibition of mutant.
bHydrogen bond interactions are indicated as direct + water-
mediated. cvan der Waals contacts are shown for major inhibitor
conformation with number for minor conformation in parentheses.
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interface and provides extensive hydrophobic interactions
connecting the ﬂaps to the active site. The loss of interactions
across the ﬂap−core interface in the PRL76V mutant is expected
to inﬂuence ﬂap mobility and promote inhibitor dissociation
from the dimer. This eﬀect is consistent with the observations
of increased dimer dissociation and decreased dimer stability.24
Increased conformational ﬂexibility of the ﬂaps in the PRL76V
mutant compared to the wild-type enzyme was reported in 1 ns
molecular dynamics simulations of the complexes with
inhibitor 2 consistent with increased calculated interaction
free energy and clinical resistance.36
■ DISCUSSION
Drug-resistant mutation L76V is rare in clinical isolates of
HIV; however, this mutation alone acts to decrease the
stability of the PR dimer, alters precursor processing, and
reduces viral ﬁtness.20,24,37 In this study, we examined the
eﬀect of four antiviral inhibitors, two clinical drugs and two
investigational inhibitors, on the single mutant PRL76V. These
inhibitors exhibit diﬀerent chemical structures and binding
interactions with the PR.
The tested inhibitors have Ki values of ∼2−8 nM for PRL76V,
which are 2−3 orders of magnitude worse compared to values
reported for the wild-type enzyme.7,12,16 None of these
inhibitors were more eﬀective than 1 for the mutant PRL76V.
Inhibition of PRL76V by 1 has been reported as 0.79 nM
24 or
1.5-fold worse25 than for wild-type enzymes in diﬀerent assays
with two distinct substrates. GRL-02031, a diﬀerent antiviral
inhibitor based on the 1 scaﬀold, also gave an inhibition
constant of 0.8 nM for PRL76V, consistent with decreased
interactions of the P1′ pyrrolidinone group with PR atoms.26
In contrast to other tested inhibitors, 6 exhibited similar
inhibition of the PRL76V mutant compared to wild-type
enzymes, consistent with retaining antiviral eﬀectiveness.19,20,24
In the current study, 5 was the better of the two investigational
inhibitors with Ki of 1.9 nM for PRL76V, possibly due to the two
halide interactions with the carbonyl oxygen of Gly48 in the
ﬂap. Compounds 3 and 4 showed the worst inhibition, which
suggests neither the larger tris-THF group at P2 in 4 nor the
direct interactions of 3 with the ﬂaps are beneﬁcial for binding
to this mutant.
The structures of PRL76V−inhibitor complexes are very
similar to the corresponding wild-type enzyme structures. Only
inhibitor 5, which was the best inhibitor of the four for PRL76V,
showed distinct changes in the interactions of the aniline
amine with alternate conformations of Asp30′. Elongations of
water-mediated bonds by up to 0.3 and 0.4 Å, respectively,
were observed in complexes 3 and 4. The active-site
interactions with 2 were essentially identical in both the
wild-type and the mutant. Fewer van der Waals contacts
occurred with the mutant compared to wild-type enzymes for
inhibitors 3, 4, and 5, whereas inhibitors 1, 2, and 6 showed
the opposite eﬀect. Therefore, the mechanism of resistance
does not seem to rely solely on the loss of active-site
interactions with inhibitors. Mutation L76V is not unusual in
this respect; mutations L90M and N88D/S also have no direct
interactions with inhibitors, yet are strongly associated with
resistance to one or more clinical inhibitors.2,38
The rarity of L76V as a single mutation in clinical samples, at
0.4%,20 may be due to its debilitating eﬀects on precursor
processing. Furthermore, the slower turnover of substrate and
poor inhibition may arise from alterations in the dynamics of
ﬂap opening and closing rather than altered interactions with
inhibitors. The mutation is likely to confer resistance by a
mechanism that is independent of the inhibitor interactions in
the active site. Instead, the loss of interactions of Val76 with
residues at the base of the ﬂap could increase ﬂap mobility. If
the virus accumulates additional mutations, as observed in
3.2% of clinical samples,20 these mutations might compensate
for the loss of stability because of L76V, while retaining
resistance to a speciﬁc drug.
Interestingly, ﬁve of the seven residues adjacent to Leu76 in
the PR structure are sites of major resistance mutations, D30N,
V32I, I47V, Q58E, and T74P2. Of these, only the resistance
mutation Q58E is strongly associated with L76V in resistant
mutants.2,39 Experimental studies corroborate ﬁndings from
statistical analyses. Mutation L76V, which is associated with
resistance to 1, is selected during viral passage with increasing
concentrations of 1.40 In contrast, L76V is associated with
increased susceptibility to 6 and atazanavir, and experiments
suggest that L76V re-sensitizes multi-drug resistant viruses to
therapy with those two inhibitors.19 Flap mutation M46I is
strongly associated with L76V as shown by a large proportion
of coprevalence in L76V-containing sequences.20,39,41 Impaired
autoprocessing of precursor PR-containing L76V is partly
rescued by addition of a second mutation of M46I24 and,
although L76V reduces viral replication, viral ﬁtness is partly
rescued by combination with this mutation.37 The eﬀects of
combining L76V with other mutations on the structure and
dynamics of the PR dimer have not yet been explored.
An inhibitor capable of forming strong interactions with
residues 45−47 of the ﬂaps might assist in retaining a closed
conformation dimer, and be eﬀective against resistant mutants
with defects such as those observed for L76V. Therefore, this
hydrophobic region between the ﬂaps and the outer edge of
the active site in each monomer is a potential target site that
should be considered during the design of next-generation
inhibitors for resistant viruses.
Figure 4. Hydrophobic interactions of residue 76. Hydrophobic
interactions are shown for inhibitor 3 complexes with (A) PRWT and
(B) PRL76V. The main chain of PR is shown as gray ribbons. The side
chains are represented by sticks with Cα atoms as spheres. The tip of
the ﬂap in the second subunit of the dimer is shown as black cartoons.
Leu76 is green, Val76 is red, and side chains of residues that lose
interactions in the mutant are shown in purple in (B). The number of
van der Waals contacts of the side chain of residue 76 with
neighboring residues is indicated next to each dotted line.
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■ EXPERIMENTAL SECTION
Enzymes and Inhibitors. PRWT and PRL76V proteins
contain optimizing mutations Q7K/L33I/L63I to reduce
autoproteolysis and C67A/C95A to prevent thiol bond
formation.42 Recombinant PR was expressed in Escherichia
coli BL21 DE(3) and puriﬁed by size-exclusion chromatog-
raphy followed by reverse phase chromatography as described
previously.43 PR was refolded via buﬀer-exchange dialysis in 25
mM formic acid and 1 mM dithiothreitol. PR was activated via
buﬀer-exchange dialysis in 50 mM sodium acetate, pH 5.0. PR
was concentrated to 3.5−5.0 mg/mL for crystallization or
further diluted for inhibition assays as needed. Inhibitors 2 and
3 with HPLC purity of 99.3 and 100%, respectively, were
obtained from the AIDS Reagent Program, Division of AIDS,
NIAID, NIH. Inhibitors 4 and 5 (>95% purity by HPLC) were
provided by Dr. Arun Ghosh at Purdue University.
Enzyme Inhibition Assays. A continuous kinetic assay
employing a Foster resonance energy transfer substrate analog
of the HIV-1 p2/NC cleavage site (Abz−Thr−Ile−Nle−p-
nitro-Phe−Gln−Arg−NH2 where Abz is anthranilic acid, Nle
is norleucine, and p-nitro-Phe is p-nitrophenylalanine) was
performed as previously described.26 Microtiter plates (96-
well) were loaded with 10 μL PR stock (ﬁnal well
concentration 12−26 nM determined via active-site titration
with tight binding inhibitor), 98 μL reaction buﬀer (0.1 M 2-
morpholinoethanesulfonate (MES), pH 5.6, 0.4 M NaCl, 1
mM ethylenediaminetetraacetic acid, and 5% glycerol), and 2
μL inhibitor in dimethyl sulfoxide (DMSO) (ﬁnal well
concentration of 0−100 nM). Samples were equilibrated at
25 °C for 5 min and the reactions were measured at the same
temperature. The reactions were initiated by addition of 90 μL
substrate at a ﬁnal well concentration of 81 μM. Reactions
were measured under steady-state conditions using a PolarStar
Optima (BMG Labtech) with emission wavelength at 340 nm
and excitation wavelength at 420 nm. Fluorescence resulting
from substrate hydrolysis at each inhibitor concentration [I]
was measured and plotted against time. Initial velocities (V0),
corresponding to the slope per minute of each reaction, were
determined using MARS software (BMG Labtech). A dose−
response plot of V0 versus [I] was constructed using SigmaPlot
(Systat Software) by nonlinear regression curve ﬁtting to
determine IC50. Reactions were performed in triplicate, and Ki
values were calculated from IC50 using the tight-binding
inhibitor equation Ki = (IC50 − 0.5[E])/(1 + [S]/Km).44 The
Km for PRL76V at 37 μM was determined previously under
similar conditions.24
Protein Crystallization. Each inhibitor suspended in
DMSO was complexed with PR on ice at a molar ratio of at
least 5:1 and crystallized using vapor diﬀusion hanging drop
method. Each drop contained equal volumes of protein and
reservoir solution. Crystals grew in 0.8−1.5 M sodium chloride
as precipitant. Crystals for most complexes grew in 0.1 M
sodium acetate, pH 4.0−5.4, as buﬀer. Buﬀers used for
crystallization for the following were exceptions: 0.1 M MES,
pH 5.6, for PRWT in complex with 2, and 0.1 M citrate
phosphate, pH 6.0, for PRL76V in complex with 2. Moreover,
5% DMSO was used for crystallization conditions of PRL76V
complexes with 2 and 3. Crystals were soaked in reservoir
solution with 30% glycerol (v/v) as cryoprotectant and then
ﬂash-frozen in liquid nitrogen.
X-ray Diﬀraction, Processing, and Reﬁnement. X-ray
diﬀraction data were collected remotely using Southeastern
Regional Collaborative Access Team ID-22 and BM-22
beamlines of the Advanced Photon Source in Argonne
National Laboratory (Argonne, IL). Diﬀraction data were
indexed, integrated, and scaled using HKL-2000.45 Molecular
replacement was performed using CCP4 Phaser46,47 with PRWT
in complex with amprenavir (PDB 3NU3) as the initial model.
Structures were reﬁned iteratively with Coot48 and SHELX.49
The inhibitor and any side chains with incomplete 2Fo − Fc
density were removed during the initial rounds of reﬁnement
to avoid bias, and atoms were added according to density in Fo
− Fc omit maps. Alternate conformations were modeled if
visible in the electron density maps for the inhibitor and
protein residues. Anisotropic B factors were included in the last
stages of reﬁnement for all structures, except for the lowest
resolution structure of PRL76V in complex with 4. Structures
were analyzed using Coot, CCP4 Superpose, CCP4 Baverage,
CCP4 Contact, and CCP4 Sfcheck. Illustrations were created
using PyMol (Schrödinger, LLC.).
Crystallographic coordinate and structure factors have been
deposited in the Protein Data Bank with accession codes 6DJ1
for PRWT−2, 6DJ2 for PRL76V−2, 6DIF for PRWT−3, 6DIL for
PRL76V−3, 6DJ5 for PRL76V−4, and 6DJ7 for PRL76V−5. The
authors will release the atomic coordinates and experimental
data upon article publication.
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